Agios Pharmaceuticals Inc. (AGIO)
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
AGIO Stock Surges 35% in Six Months: What's Driving It?
Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new ITP rights add to its rare blood disease push.
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
Agios Pharmaceuticals NASDAQ: AGIO used an investor webcast tied to the 2026 European Hematology Association Congress in Stockholm to highlight new clinical data for mitapivat across thalassemia and sickle cell disease, while outlining a broader rare disease strategy that now includes multiple hematology and metabolic programs.
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate
Agios gains global rights to cevidoplenib for ITP, adding a late-stage rare hematology asset with up to $1B U.S. peak sales potential.
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes
Agios discontinues development of tebapivat in lower-risk MDS after a phase IIb study misses efficacy goals, shifting focus to a phase II SCD program.
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?
AGIO's Pyrukynd Gets Approval for Thalassemia in Europe
Agios wins EU approval for Pyrukynd in adult thalassemia patients, expanding the drug's reach as the only authorized therapy for a broad patient population.
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
Agios Pharmaceuticals NASDAQ: AGIO executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently submitted supplemental new drug application for sickle cell disease during a presentation at the 2026 RBC Capital Markets Global Healthcare Conference.
